|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial显示文摘 | JY Douillard D Cunningham AD Roth M Navarro RD James P Karasek P Jandik T Iveson J Carmichael M Alakl G Gruia L Awad P Rougier | 2000 | The Lancet2000，，9209： | 4 |
| 2 | Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis显示文摘AIM To confirm previous conclusions on Saccharomyces cerevisiae(S. cerevisiae) CNCM I-3856 for irritable bowel syndrome(IBS) management.METHODS An individual patient data meta-analysis was performed on two randomized clinical trials studying the effect of S. cerevisiae CNCM I-3856 supplementation on gastrointestinal(GI) symptoms in IBS subjects. A total of 579 IBS subjects were included. Outcomes were the daily Likert scale scores of abdominal pain/discomfort and bloating [area under the curve(AUC) and weekly means], responder status, and bowel movements(stool frequency and consistency). Statistical analyses were conducted in Intent to Treat(ITT) population, IBS-C subjects and IBS-C subjects with an abdominal pain/discomfort score higher than or equal to 2 at baseline('IBS-C ≥ 2 subpopulation').RESULTS S. cerevisiae CNCM I-3856 significantly improved abdominal pain/discomfort and bloating during the second month of supplementation [AUC(W5-W8)]with improvement up to the minimal clinically relevant threshold of 10%: a 12.3% reduction of abdominal pain/discomfort in the ITT population compared to the Placebo group(P = 0.0134) has been observed. In the IBS-C ≥ 2 subpopulation, there were a 13.1% reduction of abdominal pain/discomfort and a 14.9% reduction of bloating compared to the Placebo group(P = 0.0194 and P = 0.0145, respectively). GI symptoms significantly decreased during supplementation but no statistical differences were reported between groups at the end of the supplementation period. Responder status was defined as a subject who experienced a decrease of 1 arbitrary unit(a.u.) or 50% of the abdominal discomfort score from baseline for at least 2 wk out of the last 4 wk of the study. A significant difference between groups was reported in the ITT population, when considering the first definition: subjects in the Active group had 1.510 higher odds to be a responder(reduction of 1 a.u. of abdominal pain/discomfort) compared with subjects in the Placebo group(P = 0.0240). At the end of supplementation period, stool consistency in the Active group of the ITT population was significantly improved and classified as 'normal' compared to Placebo(respectively 3.13 ± 1.197 a.u. vs 2.58 ± 1.020 a.u., P = 0.0003). Similar results were seen in the IBS-C ≥ 2 subpopulation(Active group: 3.14 ± 1.219 a.u. vs Placebo group: 2.59 ± 1.017 a.u., P = 0.0009).CONCLUSION This meta-analysis supports previous data linking S. cerevisiae I-3856 and improvement of GI symptoms, in IBS overall population and in the IBS-C and IBS-C ≥ 2 subpopulations. | Amélie Cayzeele-Decherf Fanny Pélerin Sébastien Leuillet Benoit Douillard Béatrice Housez Murielle Cazaubiel Gunnard K Jacobson Peter Jüsten Pierre Desreumaux | 2017 | World Journal of Gastroenterology2017，23，2： | 2 |
| 3 | Phase Ⅱ study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy显示文摘 | Rougier P Bugat R Douillard JY | 1997 | J Clin Oncol1997，15，1： | 1 |
| 4 | Efficacy of 5-Fu+DDP compared to bolus 5-Fu in advanced pancreatic cacinoma:a radomized trial from the French Anticancer Centers Digestive Group (FNLCCDG) 显示文摘 | Rougier P Ducreux M Douillard JY | 1999 | Pro Am Soc Oncol1999，18，8： | 1 |
| 5 | Iteratlve corection of intersymbol interference: Turbo-equalization 显示文摘 | DOUILLARD C PICART A DIDIER P | 1995 | European Trans Telecommun1995，6，5： | 1 |
| 6 | Multicenter phase III study of uracil/tegafur and oral leucovin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer显示文摘 | Douillard J Y Hoff P M Skillings J | 2002 | J Clin Oncol2002，20，17： | 1 |
| 7 | Iterative correction of inter-symbol interference: Turbo-equalization 显示文摘 | DOUILLARD C PICART A DIDIER P | 1995 | European Trans Telecomm1995，6，5： | 1 |
| 8 | Docetaxelplus cisplatin:An active and well-tolerated combination inpatients for advanced non small cell lung cancer 显示文摘 | LE CHEVALIER T MONNIER A DOUILLARD P | 2008 | EuropeanJournal of Cancer2008，，： | 1 |
| 9 | Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer:an open-label multicenter phase Ⅱ study显示文摘 | Ychou M Douillard JY Rougier P | 2000 | Am J Clin Oncol2000，23，2： | 1 |
| 10 | Randomized phase Ⅲ trial of gemcibatine/cisplatin and protein kinase Cα antisense oligonucleofide apfinocarsen in patients with advanced stage non-small-cell lung cancer 显示文摘 | Paz-Ares L Douillard JY Koralewski P | 2005 | Proc Am Soc Clin Oncol2005，24，63： | 1 |
| 11 | Anti TCR specific DNA vaccination demonstrates a role for a CD8+ T cell clone in the induction of allograft to lerance by donor specific blood transfusion显示文摘 | Vignes C Chiffoleau E Douillard P | 2000 | J Immunol2000，165，1： | 1 |
| 12 | A critical for transforming growth factor-beta in donor transfusion- induced allograft tolerance显示文摘 | Josien R Douillard P Guillot C | 1998 | J Clin Invest1998，102，11： | 1 |
| 13 | Docetaxel plus cisplatin:An active and well-tolerated combination in patients for advanced non small cell lung cancer显示文摘 | LE CHEVALIER T MONNIER A DOUILLARD P | 1998 | Eur J Cancer1998，34，13： | 1 |
| 14 | Phase Ⅱ study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy显示文摘 | Rougier P Bugat R Douillard JY | 1997 | J Clin Oncol1997，15，1： | 1 |
| 15 | Multicenter phase III study of uracil/tegafur and oral leucovin versus fluorouracil and leucovin in patients with previously untreated metastatic colorectal cancer显示文摘 | Douillard J Y Hoff P M Skillings J | 2002 | J Clin Oncol2002，20，6： | 1 |
| 16 | Iterative correction of intersymbol interference : Turbo-equalization显示文摘 | Douillard C Picart A Didier P | 1995 | European Trans Telecommun1995，6，5： | 1 |
| 17 | Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopo- lysaccharide and dexamethasone in parenchymal and non- parenehymal rat liver cell显示文摘 | Muschen M Warskulat U Douillard P etal | 1998 | Hepatology1998，27，1： | 1 |
| 18 | Iterative correction of intersymbol interference: Turbo-equalization显示文摘 | Douillard C Picart A Didier P | 1995 | European Trans Telecommun1995，6，5： | 1 |
| 19 | The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor显示文摘 | Douillard P Awwad RA | 2000 | J Biol Chem2000，275，1： | 1 |
| 20 | Iterafive Correction of Intersymbol Interference:Turbo Equalization显示文摘 | PICART A DIDIER P | 1995 | European Trans Telecommun1995，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员